Paolo Tarantino, MD is an Advanced Research Fellow in the Breast Oncology Program at Dana-Farber Cancer Institute and Harvard Medical School.

Dana Chase, MD, is an associate professor of obstetrics and gynecology in the Division of Gynecologic Oncology at UCLA Health.

Andrea Necchi, MD, is an associate professor at Vita-Salute Raffaele University and the head of genitourinary medical oncology at IRCCS San Raffaele Hospital and Scientific Institute in Italy.

, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, 

 covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

, leading oncologists reflected on data expected to redefine practice across breast, genitourinary, and gynecologic malignancies.

Paolo Tarantino, MD, PhD, a breast medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School in Boston, Massachusetts, highlighted multiple paradigm-shifting studies across breast cancer subtypes. He pointed to results from the phase 3 DESTINY-Breast11 trial (NCT05113251), in which neoadjuvant fam-trastuzumab deruxtecan-nxki (Enhertu) plus a taxane, trastuzumab (Herceptin), and pertuzumab (Perjeta; THP) improved pathologic complete response rates and reduced cardiotoxicity vs dose-dense doxorubicin and cyclophosphamide plus THP in patients with early-stage HER2-positive early breast cancer. He also noted findings from the phase 3 TROPION-Breast02 (NCT05374512) and ASCENT-03 (NCT05382299) trials, which showed that datopotamab deruxtecan-dlnk (Datroway) and sacituzumab govitecan-hziy (Trodelvy), respectively, significantly prolonged progression-free survival in metastatic triple-negative breast cancer.

Andrea Necchi, MD, an associate professor of oncology at Vita-Salute San Raffaele University in Milan, Italy, and Andrew W. Hahn, MD, an assistant professor of genitourinary medical oncology at The University of Texas MD Anderson Cancer Center in Houston, discussed key advances in genitourinary cancers. Necchi highlighted the perioperative findings from the phase 3 KEYNOTE-905/EV-303 trial (NCT03924895) of enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) in muscle-invasive bladder cancer and the phase 3 RC48-C016 study (NCT05302284) evaluating disitamab vedotin (PF-08046051) plus toripalimab (Loqtorzi) vs chemotherapy in HER2-expressing locally advanced or metastatic urothelial carcinoma. Hahn pointed to the phase 2 OPTIC RCC (NCT05361720) and phase 1b/2 KEYMAKER-U03 (NCT04626479) substudy 03A studies in renal cell carcinoma, emphasizing the growing role of biomarker-driven therapy selection and the potential for triplet regimens in future frontline management.

Dana M. Chase, MD, a professor of clinical obstetrics and gynecology at UCLA, highlighted several gynecologic oncology trials presented at the meeting, including the phase 3 KEYNOTE-B96 trial (NCT05116189) of pembrolizumab plus chemotherapy in recurrent platinum-resistant ovarian cancer, which demonstrated an overall survival benefit in a difficult-to-treat population. She also underscored emerging data for next-generation antibody-drug conjugates targeting CLDN6, HER2, and folate receptor α, which continue to show durable efficacy and improved tolerability in ovarian and endometrial cancers.

Nicoletta Colombo, MD, PhD, director of the Gynecologic Oncology Program at the European Institute of Oncology IRCCS in Milan, Italy, highlighted several noteworthy presentations at the 2025 ESMO Congress, including updates in ovarian cancer and emerging data in cervical and endometrial malignancies. She noted particular interest in studies evaluating chemotherapy-free regimens in the frontline treatment of cervical cancer and additional analyses in endometrial cancer that, while not practice changing, provide valuable insights to refine therapeutic strategies and expand the treatment armamentarium for patients with gynecologic cancers.

That’s all we have for today! Thank you for listening to this episode of 

. Check back throughout the week for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit 

 is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

*OncLive On Air is available on: Apple Podcasts, Spotify, CastBox, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Podcasts

At the 2025 ESMO Congress, leading oncologists reflected on data expected to redefine practice across breast, genitourinary, and gynecologic malignancies.

Oncology Experts Dive Into Top Data From ESMO 2025

Andrew W. Hahn, MD, assistant professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the investigation of lenvatinib (Lenvima) plus everolimus (Afintor) vs cabozantinib (Cabometyx) in metastatic renal cell carcinoma (RCC) following progression on an immune checkpoint inhibitor.

The phase 2 LenCabo trial (NCT05012371) is evaluating lenvatinib plus everolimus vs cabozantinib monotherapy in patients with metastatic RCC who have progressed on a PD-1/PD-L1 immune checkpoint inhibitor and have received 1 to 2 lines of prior therapy.

In clinical practice, many patients receive cabozantinib as second-line therapy, and lenvatinib plus everolimus is typically administered as a third-line therapy, since lenvatinib has shown activity in patients who progress on cabozantinib, Hahn explains. Although cabozantinib and lenvatinib are both multitargeted TKIs, they have distinct mechanisms of action, Hahn adds.

The phase 2 study was initiated to compare lenvatinib plus everolimus vs cabozantinib monotherapy in a head-to-head trial that's designed to reflect contemporary practice, Hahn continues. Although the prevailing assumption is that the efficacy, toxicity, and impact on quality of life are similar between the 2 regimens, direct comparison in a prospective trial could shed additional light differences between them, Hahn concludes.

Videos

Andrew W. Hahn, MD, discusses the investigation of lenvatinib plus everolimus vs cabozantinib in metastatic renal cell carcinoma following progression on an immune checkpoint inhibitor.


Andrew W. Hahn, MD

Articles

Oncology Experts Dive Into Top Data From ESMO 2025

Dr. Hahn on the Investigation of Lenvatinib/Everolimus Vs Cabozantinib in mRCC